PN and RFA offer similar survival for cT1a RCC tumors ≤2 cm, but PN is superior for larger tumors. RFA may be considered for elderly patients with comorbidities, especially for tumors ≤2 cm. PN ...

Partial and radical nephrectomy for T3a RCC have similar 5-year rates of overall and cancer-specific survival, according to a propensity score-matched analysis. WASHINGTON, DC—Partial nephrectomy (PN) ...

In a retrospective study of patients treated at expert centers, RAPN for localized cT2 renal tumors did not compromise oncologic outcomes and better preserved renal function compared with minimally ...

An international study examined outcomes between a single-port (SP) versus a multi-port (MP) approach to RAPN, with a focus on elderly patients. Despite similar demographics among patients ≤64 years ...

Extended multi-centre review of adjuvant pembrolizumab for renal cell carcinoma. Head-to-head comparison of pembrolizumab-axitinib versus pembrolizumab-lenvatinib in metastatic RCC: Real world data ...

First preliminary results of artificial intelligence-generated, explainable treatment recommendations for renal cell cancer based on multidisciplinary cancer conferences. Multivariate adjusted ...

The renal cancer pipeline presents key opportunities in developing novel therapies targeting immunosuppression and oncogenic pathways. Notable advancements include combinations like Quavonlimab with ...

A Canadian study recently assessed 709 patients with intermediate- and high-risk synchronous mRCC with or without sarcomatoid features. Most patients had clear cell histology and were treated with ...

Please provide your email address to receive an email when new articles are posted on . Patients with diabetes achieved shorter OS than those without diabetes. Other predictors of shorter survival ...

Cystic renal cell carcinoma is a rare type of cancer. A person may develop cystic renal cell carcinoma if they have treatment for the last stages of kidney failure. Cystic renal cell carcinoma (CRCC) ...